[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2528366T3 - Citicoline for the treatment of glaucoma - Google Patents

Citicoline for the treatment of glaucoma Download PDF

Info

Publication number
ES2528366T3
ES2528366T3 ES11711656.6T ES11711656T ES2528366T3 ES 2528366 T3 ES2528366 T3 ES 2528366T3 ES 11711656 T ES11711656 T ES 11711656T ES 2528366 T3 ES2528366 T3 ES 2528366T3
Authority
ES
Spain
Prior art keywords
glaucoma
treatment
citicoline
vehicles
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11711656.6T
Other languages
Spanish (es)
Inventor
Cristiano Virno
Marco Malizia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OMIKRON ITALIA Srl
Original Assignee
OMIKRON ITALIA Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OMIKRON ITALIA Srl filed Critical OMIKRON ITALIA Srl
Application granted granted Critical
Publication of ES2528366T3 publication Critical patent/ES2528366T3/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición oftálmica de uso tópico para el tratamiento del glaucoma, que contiene citicolina y uno o más vehículos, siendo dicho vehículo un agente aumentador de la viscosidad.Ophthalmic composition for topical use for the treatment of glaucoma, which contains citicoline and one or more vehicles, said vehicle being a viscosity increasing agent.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

Claims (1)

imagen1image 1
ES11711656.6T 2010-02-22 2011-02-17 Citicoline for the treatment of glaucoma Active ES2528366T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM20100071 2010-02-22
ITRM2010A000071A IT1398378B1 (en) 2010-02-22 2010-02-22 CYTICOLINE FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION.
PCT/IB2011/050663 WO2011101802A1 (en) 2010-02-22 2011-02-17 Citicoline for the treatment of glaucoma and ocular hypertension

Publications (1)

Publication Number Publication Date
ES2528366T3 true ES2528366T3 (en) 2015-02-09

Family

ID=42790833

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11711656.6T Active ES2528366T3 (en) 2010-02-22 2011-02-17 Citicoline for the treatment of glaucoma

Country Status (7)

Country Link
US (1) US8822429B2 (en)
EP (1) EP2538918B1 (en)
JP (1) JP5801324B2 (en)
ES (1) ES2528366T3 (en)
IT (1) IT1398378B1 (en)
PL (1) PL2538918T3 (en)
WO (1) WO2011101802A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20120284A1 (en) * 2012-06-18 2013-12-19 Omikron Italia S R L CITICOLINE FOR THE TREATMENT OF DIABETIC RETINOPATHY.
ITMI20121223A1 (en) * 2012-07-13 2014-01-14 Gregorio Fabio De NEW PHARMACOLOGICAL COMPOSITION INCLUDING CITICOLINE IN COMBINATION WITH GLYCEROL AND / OR ACETAZOLAMIDE
CA2885369A1 (en) * 2012-09-28 2014-04-03 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
DK2968385T3 (en) 2013-03-13 2018-09-03 Univ Tufts URIDINNUCLEOSIDE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR USING THEREOF
ITUA20161679A1 (en) * 2016-03-15 2017-09-15 Neuraxpharm Italy S P A COMPOSITION TO PREVENT AND TREAT NEURODEGENERATIVE PATHOLOGIES AND COGNITIVE DISORDERS
IT201600103956A1 (en) * 2016-10-17 2018-04-17 Omikron Italia S R L OPHTHALMIC FORMULATION INCLUDING CYTICOLINE VEHICULATED BY LIPOSOMAS FOR THE TREATMENT OF GLAUCOMA
IT202200021624A1 (en) * 2022-10-20 2024-04-20 Sifi Spa NUTRACEUTIC COMPOSITION WITH NEUROPROTECTIVE EFFECT FOR THE TREATMENT OF GLAUCOMA

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303627D0 (en) * 1993-11-03 1993-11-03 Kabi Pharmacia Ab Method and means for the prevention of cataract

Also Published As

Publication number Publication date
WO2011101802A1 (en) 2011-08-25
EP2538918B1 (en) 2014-11-19
US20120316128A1 (en) 2012-12-13
EP2538918A1 (en) 2013-01-02
JP5801324B2 (en) 2015-10-28
IT1398378B1 (en) 2013-02-22
JP2013520406A (en) 2013-06-06
US8822429B2 (en) 2014-09-02
ITRM20100071A1 (en) 2011-08-23
PL2538918T3 (en) 2015-05-29

Similar Documents

Publication Publication Date Title
ES2528366T3 (en) Citicoline for the treatment of glaucoma
ES2649340T3 (en) Administration of hypoxia activated drugs and antiangiogenic agents for cancer treatment
CL2017003436A1 (en) Benzoxacepin oxazolidinone compounds and methods of use
CL2015001207A1 (en) Composition for preventing or treating diabetes, diabesity or diabetic complications, comprising an oxintomodulin analog; and use of the composition.
CL2017001488A1 (en) Benzamides substituted with 1,3-thiazol-2-yl
CL2011001811A1 (en) A method of treating a patient who has suffered an acute myocardial infarction that comprises the use of an antifibrotic agent.
CL2012003281A1 (en) Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
CL2014002406A1 (en) Method for the treatment of refractory or resistant treatment depression comprising administering esketamine intravenously or intranasally alone or in combination with one or more antidepressants; pharmaceutical composition; and its use in the treatment of refractory or treatment resistant depression.
CL2011001255A1 (en) Pharmaceutical combinations comprising an antibody that specifically recognizes cd38 and at least vincristine; and use of the antibody that specifically recognizes cd38 for the treatment of cancer.
CL2012003415A1 (en) Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer.
BR112015022625A2 (en) microarrays for therapeutic agent delivery and methods of use
BR112016009071A8 (en) COSMETIC COMPOSITION IN THE FORM OF NANOFIBERS, COMPOSITION PRODUCTION METHOD AND USE
BR112015022170A2 (en) tire having a split carcass canvas construction
CL2017002214A1 (en) Combination formulation of tesofensin and beta blocker
CL2011000165A1 (en) Compounds derived from indolinones; pharmaceutical composition comprising said compound; and use of the compound for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2008000110A1 (en) USE OF COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED FOR THE TREATMENT OF METABOLIC SYNDROME; AND COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED.
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
BR112018009488A2 (en) absorbent core layer and absorbent article
CL2016001578A1 (en) Piperidinyltetrahydroquinolines substituted and their use as antagonists of alpha-2c adenoreceptors.
PE20150167A1 (en) (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL
NI201500175A (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER
CL2015002113A1 (en) Azetidinloxyphenylpyrrolidine compounds
CL2016000019A1 (en) Compounds derived from deuterated dihydroxyphenyl or a salt thereof; pharmaceutical composition that comprises them and their use for the treatment of neurotransmitter-mediated disorders such as hypotension, sleep disorders, Alzheimer's disease and depression.
CL2013000599A1 (en) Compounds derived from dicyano-pyridine, selective agonists of adenosine a1, for use in a procedure for the treatment and / or prophylaxis of glaucoma, normotensive glaucoma, ocular hypertension and / or combinations thereof; and pharmaceutical composition comprising one of said compounds.
ES2534911T3 (en) Use of plasmin for the treatment of filtration failure after trabeculectomy